Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Launched by ASTRAZENECA · Jun 17, 2024

Keywords

ClinConnect Summary

The CORSAR trial is a study focused on understanding the characteristics of adults with uncontrolled severe asthma in Russia. Researchers are looking to gather information from about 5,000 patients across 50 outpatient centers in various regions. Participants must be at least 18 years old and have a diagnosis of uncontrolled severe asthma, which means their asthma symptoms are not well managed despite receiving standard treatments. This study is observational, meaning it does not involve any new treatments or changes to how patients are currently cared for; instead, it aims to collect data based on routine medical practices.

To be eligible, patients should have had their asthma diagnosed as uncontrolled for at least a year and must have medical records showing their condition. However, those currently on certain advanced therapies or with other significant lung diseases will not be included. Participants can expect to share their health information through routine check-ups, helping researchers better understand severe asthma and potentially improve future care for others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years at the time of inclusion;
• • 2. Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;
• • 3. Patients with diagnosis of uncontrolled SA (Asthma Control Questionnaire-5 (ACQ-5) score \> 1,5) established no less than 52 weeks prior to inclusion; Severe asthma is defined as asthma, that is controlled due to treatment with ICS in medium or high doses plus LABA and/or ALP, and/or LAMA, and/or systemic corticosteroids (sCS), and/or immunobiological therapy, while attempts to reduce the volume of therapy lead to a loss of symptom control, or asthma remains uncontrolled despite this treatment. Such therapy should be carried out at least 3 months before inclusion.
• • Uncontrolled asthma is defined as ACQ-5\>1.5.
• • 4. Patients with the availability of at least 52 weeks of follow-up data (prior to inclusion) in the medical records.
• Exclusion Criteria:
• • 1. Patients receiving any biological therapy currently or within 52 weeks prior to inclusion;
• • 2. Presence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (ILF) currently or in the anamnesis;
• • 3. The participation in any clinical study currently or within 52 weeks prior to inclusion;
• • 4. An acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results.